A Phase 2a Study Evaluating the Efficacy and Safety of Sutetinib in Patients with Advanced Non–small-Cell Lung Cancer (NSCLC) Harboring Uncommon EGFR Mutations.
JOURNAL OF CLINICAL ONCOLOGY（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要
JOURNAL OF CLINICAL ONCOLOGY（2023）